✦ LIBER ✦

Circulating free DNA, p53 antibody and mutations of KRAS gene in endometrial cancer

✍ Scribed by Bozena Dobrzycka; Slawomir J. Terlikowski; Andrzej Mazurek; Oksana Kowalczuk; Wieslawa Niklinska; Lech Chyczewski; Marek Kulikowski

Publisher: John Wiley and Sons
Year: 2010
Tongue: French
Weight: 616 KB
Volume: 127
Category: Article
ISSN: 0020-7136
DOI: 10.1002/ijc.25077

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

This study was conducted to evaluate the significance of circulating free DNA (CFDNA), p53 antibody (p53‐Ab) and mutations of KRAS gene in the development of endometrial cancer (EC). A total of 109 patients with EC (87 patients with Type I and 22 patients with Type II) took part in this study. KRAS mutations and CFDNA were detected by means of the PCR‐RFLP and enriched by the PCR‐RFPL method. ELISA was used to analyze plasma p53‐Ab. Tissue expression of P53 protein was evaluated immunohistochemically (IHC). The frequency of KRAS mutations was especially high in Grade 2 of Type I EC. CFDNA was frequently detected in patients with early stage of Type II EC at a low level of grade. It is noteworthy that the p53‐Ab positive rate increased in the higher grade of Type I tumors. A significant difference in the number of cases with the p53‐Ab was found in the advanced stage of Type I tumors. The frequency of KRAS and p53‐Ab correlates with tumor stage only in the Type I EC. Plasma CFDNA and p53‐Ab offer a chance to develop a procedure for EC Type II diagnosis. The association between tumor cells related to CFDNA and p53‐Ab with Type II tumor suggests that it might potentially serve as a marker in predicting the prognosis and offers a possibility to individualize treatment regimen.

📜 SIMILAR VOLUMES

Functional analysis of p53 gene and the

Functional analysis of p53 gene and the prognostic impact of dominant-negative p53 mutation in endometrial cancer

✍ Noriaki Sakuragi; Hidemichi Watari; Yasuhiko Ebina; Ritsu Yamamoto; Eric Steiner 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 182 KB 👁 1 views

## Abstract In addition to the loss of function, mutant p53 can possess a dominant‐negative effect on wild‐type p53 and may also exert gain‐of‐function activity. It is not clear whether the functional status of __p53__ mutation contributes to differences in outcome in endometrial cancer. We collect

Circulating p53 antibodies, p53 gene mut

Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous-cell carcinoma in India

✍ Ranju Ralhan; Sonia Arora; Tushar Kant Chattopadhyay; Nootan Kumar Shukla; Meera 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 French ⚖ 66 KB 👁 1 views

## Esophageal cancer (EC) in the Indian population presents in advanced stages with poor prognosis and warrants the identification of a non-invasive marker for early detection and better prognostic assessment. We have previously reported high prevalence of p53 protein accumulation in esophageal squ

DNA repair gene polymorphisms and probab

DNA repair gene polymorphisms and probability of p53 mutation in bladder cancer

✍ Mariana C. Stern; Kathleen Conway; Yu Li; Kusum Mistry; Jack A. Taylor 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB

We investigated if the presence of single nucleotide polymorphisms (SNPs) in the XRCC1, XRCC3, and XPD genes were associated with the type and frequency of p53 mutations in bladder cancer. Using a hospital-based case-control study we have previously reported risks for the XRCC1 codon 194, XRCC1 codo

Detection of human papillomavirus DNA an

Detection of human papillomavirus DNA and p53 gene mutations in human prostate cancer

✍ Suzuki, Hiroyoshi; Komiya, Akira; Aida, Sara; Ito, Haruo; Yatani, Ryuichi; Shima 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 575 KB

The relationship between integration with human papillomavirus (HPV) and p53 gene mutations in tissues of prostate cancer was examined. Tissue samples analyzed were obtained by total prostatectomy (29 stage B cancer cases) and from autopsy (22 endocrine therapy-resistant metastatic disease cases). H

Involvement of p53 gene mutations in hum

Involvement of p53 gene mutations in human endometrial carcinomas

✍ Tsuyoshi Honda; Hidenori Kato; Toshiro Imamura; Tomonao Gima; Jun-Ichi Nishida; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 1019 KB

Mutations in the p53 gene are associated with a wide variety of human malignancies. Point mutation in one allele and loss of the remaining one generally lead to inactivation of p53 protein. A high frequency of allelic losses corresponding to the I7p 13.3 region that contained the p53 gene sequence

Correlations between p53-protein accumul

Correlations between p53-protein accumulation, serum antibodies and gene mutation in colorectal cancer

✍ Pascal Hammel; Karen Leroy-Viard; Marie-Thérèse Chaumette; Jacqueline Villaudy; 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 254 KB 👁 1 views

Only half of colorectal-cancer patients elicit serum antibodies in response to intratumoral p53-gene mutations. Our study was designed to compare cellular events (p53-protein accumulation and gene mutations) with the presence of circulating anti-p53 antibodies (p53-Ab). Thirty-five colorectalcancer